Notice: This company has been marked as potentially delisted and may not be actively trading. NYSE:AMAM Ambrx Biopharma (AMAM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get Ambrx Biopharma alerts: Email Address About Ambrx Biopharma Stock (NYSE:AMAM) 30 days 90 days 365 days Advanced Chart Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Get Ambrx Biopharma alerts:Sign Up Key Stats Today's Range$28.00▼$28.0050-Day Range$27.70▼$28.0052-Week Range$6.55▼$28.15VolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$22.83Consensus RatingHold Company OverviewAmbrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.Read More… Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Ambrx Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 5th PercentileAmbrx Biopharma scored higher than 5% of companies evaluated by MarketBeat, and ranked 985th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingAmbrx Biopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAmbrx Biopharma has received no research coverage in the past 90 days.Read more about Ambrx Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ambrx Biopharma are expected to grow in the coming year, from ($1.45) to ($1.28) per share.Price to Book Value per Share RatioAmbrx Biopharma has a P/B Ratio of 9.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AMAM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmbrx Biopharma does not currently pay a dividend.Dividend GrowthAmbrx Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for AMAM. News and Social Media0.6 / 5News SentimentN/A Search Interest3 people have searched for AMAM on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ambrx Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.64% of the stock of Ambrx Biopharma is held by insiders.Percentage Held by Institutions77.28% of the stock of Ambrx Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ambrx Biopharma's insider trading history. Receive AMAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMAM Stock News HeadlinesCormorant Global Healthcare Master Fund, LP's Net WorthAugust 31, 2024 | benzinga.com14 Day AMERIBOR Average Rate (^AMBRX)May 24, 2024 | finance.yahoo.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.September 20, 2024 | Chaikin Analytics (Ad)Latest News for Johnson & Johnson Stock (NYSE:JNJ)April 5, 2024 | benzinga.comAmbrx Biopharma Inc.: Ambrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 7, 2024 | finanznachrichten.deJohnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash DealMarch 7, 2024 | markets.businessinsider.comAmbrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 6, 2024 | globenewswire.com3 Stocks to Buy That Are Up 200% or More in 2024February 23, 2024 | investorplace.comSee More Headlines AMAM Stock Analysis - Frequently Asked Questions When did Ambrx Biopharma IPO? Ambrx Biopharma (AMAM) raised $126 million in an IPO on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen acted as the underwriters for the IPO. Company Calendar Today9/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:AMAM CUSIPN/A CIK1836056 Webambrx.com Phone858-875-2400FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Target$22.83 High Stock Price Target$32.00 Low Stock Price Target$9.00 Potential Upside/Downside-18.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.28 Quick Ratio13.28 Sales & Book Value Annual Sales$7.40 million Price / Sales238.95 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book9.18Miscellaneous Outstanding Shares63,150,000Free Float62,746,000Market Cap$1.77 billion OptionableOptionable Beta-1.92 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSE:AMAM) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ambrx Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.